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Purpose: We designed the current study to determine the protective effects of lornoxicam, a cyclooxygenase (COX)
inhibitor, on recurrent herpetic stromal keratitis (HSK) and the nuclear factor-κB (NF-κB)-mediated mechanism in mice.
Methods: A corneal latent herpes simplex virus-1 (HSV-1) infected mouse model was established. Six weeks later,
Ultraviolet B (UVB) irradiation induced the recurrence. Corneal swabs were obtained and cultured with indicator cells to
determine  shedding  of  the  virus.  Lornoxicam  was  administered  intraperitoneally  daily,  beginning  one  day  before
irradiation and lasting for seven days. Saline-treated and mock-infected control groups were also studied at the same time.
Development of corneal inflammation and opacity was scored. Immunohistochemical staining and an electrophoretic
mobility shift assay were performed to evaluate the effect of lornoxicam on NF-κB activation in the corneal tissues. The
levels of tumor necrosis factor-α (TNF-α) in the cornea were determined by an enzyme-linked immunosorbent assay
(ELISA).
Results: HSV-1 reactivation induced stromal edema and opacification concomitantly with elevated activation of NF-κB
and elevated production of TNF-α. Lornoxicam treatment significantly decreased the incidence of recurrent HSK,
attenuated the corneal opacity scores, and also effectively suppressed both NF-κB activation and TNF-α expression in 
biological analysis. Histopathology examination revealed a reduced immunostaining positive cell density for NF-κB in
the cornea from lornoxicam-treated mice as well as a diminished inflammatory response.
Conclusions: Lornoxicam exerts protective effects against HSK, presumably through the down-regulation of NF-κB
activation.
Herpes  simplex  virus  (HSV)-1  is  one  of  the  leading
causes  of  infectious  corneal  blindness.  Recurrent  corneal
herpetic disease is more harmful than the primary infection
[1].  Unrestrained  inflammatory  responses  in  recurrent
herpetic stromal keratitis (HSK) may result in irreparable
histological  damage  including  corneal  neovascularization,
scarring,  and  permanent  opacities  that  lead  to  blindness.
Traditional  antiviral  therapy  is  limited  because  the
pathogenesis  of  recurrent  HSK  involves  mainly  immune-
mediated mechanisms rather than viral cytopathic effects [2].
Viral replication is an initial factor to induce recurrent HSK.
Subsequently,  activated  inflammatory  cells  begin  to
orchestrate  the  immunopathological  process  even  in  the
absence of a replicating virus in the developing period of the
disease  [3].  Therefore,  regulating  the  excessive  immune
response  is  crucial  in  controlling  progressive  visual
impairment  in  recurrent  HSK  [2].  Previous  reports  have
shown antiviral activity of a cyclooxygenase (COX) inhibitor
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against ocular infection with HSV-1 [4-6]. COX inhibitors,
which belong to anti-inflammatory drugs, may contribute to
controlling the massive immune response at an effective yet
not deleterious level. However, the concrete influence of a
COX  inhibitor  on  the  inflammatory  mediators  and  the
mechanistic basis needs further investigation.
Nuclear  factor-κB  (NF-κB),  a  critical  transcriptional
regulatory factor, regulates the expression of diverse genes
such  as  those  involved  in  cell  growth,  inflammation,  and
immune  reaction.  These  genes  include  cytokines  such  as
tumor  necrosis  factor-α  (TNF-α),  inducible  genes  such  as
COX-2 and nitric oxide synthase, and intercellular adhesion
molecule  such  as  E-selectin.  It  is  well-known  that  the
synthesis of robust amounts of proinflammatory mediators
such as TNF-α, interleukin (IL)-1β, and chemokines is crucial
in  enhancing  the  excessive  host  immune  response  during
recurrent HSK [7,8]. Therefore, NF-κB may be a particularly
important intermediate in the immunopathology of HSK. NF-
κB seems to play a key role in the signaling pathways activated
by  HSV-1,  influencing  host  immune  response.  Previous
reports  have  demonstrated  that  the  persistent  nuclear
translocation  of  NF-κB  induced  by  HSV-1  infection  is
essential for efficient viral replication [9-12]. Hence, NF-κB
can be a rational target for antiviral therapy. Collectively, it is
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1252challenging to know if the potent anti-inflammatory effect of
a COX inhibitor against viral infection acts through the down-
regulation of NF-κB activity.
In the present work, we tested our hypothesis by using
lornoxicam (LOR), a widely used COX inhibitor in a murine
HSK  model.  LOR  exhibits  a  profound  anti-inflammatory
effect  and  is  a  potent,  balanced  inhibitor  of  COX-1  and
COX-2, which may mitigate the concerns associated with
chronic specific inhibition of COX-2 [13]. Moreover, it has
great appeal because of its improved gastrointestinal safety
with less risk of systemic side effects compared to the other
oxicams [14,15]. We hypothesized that LOR would exert
therapeutic  effects  on  recurrent  HSK  by  altering  TNF-α
expression through the down-regulation of NF-κB activity.
This study may facilitate identification of novel molecular
targets for HSK therapy.
METHODS
HSV-1  virus,  animals,  and  corneal  HSV-1  infection:  The
HSV-l strain McKrae (kindly provided by Dr. Lixin Xie,
Shandong Eye Institute, Qingdao, China.) was grown and
assayed  in  human  embryo  kidney  (HEK)-293  cells  in
Dulbecco’s  modified  minimum  essential  medium  (MEM)
containing 10% fetal bovine serum, 100 U/ml of penicillin,
and 100 mg/ml of streptomycin. Cells were cultured at 37 °C
in  a  humidified  incubator  containing  5%  CO2.  To  detect
recurrent ocular virus shedding, materials from eye swabs
were plated onto the HEK-293 cells, and cytopathic effects
were then monitored for a seven-day incubation period.
Six-week-old, female ICR mice, weighing about 20 g
each, were obtained from the Shanghai Experimental Animal
Center (Shanghai, China). The mice were fed a regular diet
and kept under standard conditions with a 12-h light/12-h dark
cycle (light from 07:00−19:00). The animals’ quarters were
maintained at 21 °C−24 °C with 40%−60% humidity. All
experiment  procedures  conformed  to  the  Association  for
Research in Vision and Ophthalmology (ARVO) Statement
for the Use of Animals in Ophthalmic and Vision Research.
Prior to the experiment, all mice underwent an examination
with slit-lamp biomicroscopy (Model 900 BQ; Haag-Streit,
Bern,  Switzerland)  and  any  mice  with  anomalies  of  the
anterior segment of the eye (cornea, anterior chamber, iris, or
lens) were excluded from the study.
Two-hundred mice (180 infected and 20 mock-infected
animals) were included in the study. Animals were infected
using the methods as previously described [16]. Briefly, after
the  mouse  was  intraperitoneally  anesthetized  with  0.5%
pentobarbital (45 mg/kg bodyweight), the corneal surface of
the right eye was incised in a cross-shaped pattern with a
sterile 26 gauge needle. The medium (5 μl) containing 106
plaque forming units (pfu) of the HSV-1 McKrae strain was
pipetted directly onto the wounded cornea. Mock-infected
control mice were inoculated similarly with the cell culture
medium (5 μl) of uninfected HEK-293 cells. Each mouse in
the infected group received an intraperitoneal injection of 1
ml of pooled human serum concurrent with infection to ensure
its survival [17]. Mock-infected control mice received human
serum as well.
UVB  irradiation  and  virus  reactivation:  Six  weeks  after
inoculation,  reactivation  of  latent  HSV-1  infection  was
induced  by  Ultraviolet  B  (UVB)  irradiation.  The  primary
infection was confirmed by positive culture of HSV eye swabs
obtained three days after inoculation. The eyes of all mice
were then examined for corneal opacity before irradiation, and
only animals with clear corneas lacking permanent damage
were used. Finally, the eyes of 152 latently infected and 20
mock- infected mice were UV-irradiated and examined for
signs  of  disease  and  viral  reactivation  in  the  reactivation
phase. In brief, the right eye of every anesthetized mouse was
exposed to 300 mJ/cm2 of UVB light (Model Waldmann UV
−100L; Waldmann Co., Villingen-Schwenningen, Germany).
The irradiation intensity at the corneal surface measured using
a Waldmann UV detector device from the same company was
10.5  mW/cm2.  The  wavelength  of  this  narrow-band
phototherapy device ranges from 310 nm to 315 nm.
The eye swab materials from the mice were obtained
before (day 0) and on days 1–7 post-UV irradiation and were
cultured  in  HEK-293  cells  as  described  above  to  detect
recurrent virus shedding from the cornea. Recurrent disease
was  defined  as  stromal  opacification  for  more  than  two
consecutive days and virus shedding in tears on any day from
day 1 to day 7 post-UVB exposure (day 0 swabs served as
controls).
Drug intervention and clinical observation of corneal disease
progression: The infected and control mice were treated with
LOR  (0.4  mg/kg/day;  Nycomed  Austria  GmbH,  Linz,
Austria) by intraperitoneal injection once every day from one
day before irradiation to day 6 post-UVB irradiation. The
optimal  dose  of  LOR  was  determined  in  a  preliminary
experiment.  In  brief,  50  HSV-1-infected  animals  were
randomly divided into five groups (10 per group), irradiated
with UVB, and then treated with 0.04, 0.2, 0.4, 2.0, or 4.0 mg/
kg of LOR. No toxic side effects or intolerance reactions
occurred in any of the mice. Out of the 10 animals in each
group, 7 (0.04 mg/kg and 0.2 mg/kg LOR groups), 4 (0.4 mg/
kg and 2.0 mg/kg LOR groups), and 5 animals (4.0 mg/kg
LOR group) presented with recurrent disease. Therefore, the
dosage of 0.4 mg/kg appeared to be the minimal effective dose
for preventing viral reactivation. The 0.4 mg/kg dosage was
used  in  the  subsequent  experiment.  Saline  was  used  by
intraperitoneal injection as a placebo in the control group.
In the reactivation phase of the study, the infected and
control mice were randomly divided into the following four
groups. The first group was the test group consisting of 76
mice that were latently infected with the virus and treated with
LOR.  The  second  group  was  the  saline-treated  group
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treated with saline. The third group was the model control
group consisting of 10 mice that were mock infected and
treated with saline. The final group was the LOR control group
consisting of 10 mice mock infected and treated with LOR.
The  drug  treatment  was  prophylactically  started  one  day
before UVB irradiation and repeated for seven consecutive
days.
Corneal damage was evaluated and graded in a masked
fashion  using  a  scoring  system  described  previously  by
Keadle et al. [17]. Briefly, on the designated days after UVB
irradiation, stromal opacification was rated on a scale of 0–4
where  0  indicates  clear  stroma,  1  indicates  mild  stromal
opacification, 2 indicates moderate opacity with discernible
iris features, 3 indicates dense opacity with loss of defined iris
detail except pupil margins, and 4 indicates total opacity with
no posterior view.
Tissue  preparation  and  nuclear  protein  extraction:  Four,
seven,  ten,  fourteen,  and  twenty-one  days  after  UVB
irradiation, the mice were humanely sacrificed by cervical
dislocation and whole eyes were removed immediately. Under
an  operating  microscope,  corneas  were  quickly  dissected
without any limbal or iris tissue for analysis of NF-κB and
TNF-α. Excised corneas were frozen in liquid nitrogen and
stored at −80 °C until analysis. Corneas obtained from mock-
infected  mice  at  day  14  were  included  as  controls.  For
preparation of nuclear extracts, six corneas having reactivated
lesions  (confirmed  by  slit-lamp  biomicroscopy  and  virus-
positive  eye-swab  data)  were  collected  and  minced  at
designated time points. The nuclear extracts of two cornea
tissues were pooled and prepared by hypotonic lysis followed
by a high-salt extraction. Frozen corneas were rinsed with ice-
cold buffer A, which contained 10 mM HEPES (pH 7.9),
10  mM  KCl,  2  mM  MgCl2,  0.1  mM  EDTA,  1.0  mM
dithiothreitol  (DTT),  and  0.5  mM  phenylmethylsulfonyl
fluoride (PMSF). All chemicals were from Sigma Chemical
Co. (St Louis, MO). The homogenate was incubated on ice
for 20 min after 50 µl of 10% Nonidet P-40 was added. The
mixture was vortexed for 30 s and centrifuged (5000x g) for
1 min at 4 °C. Supernatants were harvested and stored in small
aliquots at −80 °C for analysis of TNF-α. The crude nuclear
pellets  were  re-suspended  in  200  µl  of  ice-cold  buffer  B
containing 20 mM HEPES (pH 7.9), 420 mM NaCl, 0.1 mM
EDTA, 1.5 mM MgCl2,1 mM DTT, 0.5 mM PMSF, and 25%
(v/v) glycerol and were incubated on ice for 30 min with
intermittent  mixing.  The  lysates  were  then  centrifuged  at
12000x g for 20 min at 4 °C, and the supernatants containing
the nuclear proteins were stored at −80 °C for NF-κB analysis.
Protein  concentrations  were  determined  using  a  Bradford
protein assay kit (Bio-Rad, Hercules, CA).
Electrophoretic  mobility  shift  assay:  The  NF-κB  DNA–
binding activity was measured by electrophoretic mobility
shift  assay  (EMSA)  according  to  the  manufacturer’s
instructions (Gel Shift Assay Systems; Promega, Madison,
WI).  The  NF-κB  oligonucleotide  was  end-labeled  with
[γ-32P]  ATP  (Free  Biotech,  Beijing,  China)  using  T4-
polynucleotide kinase. Binding reactions were performed by
adding 10 µg of nuclear extracts to 7 µl of binding buffer
containing 10 mM Tris-HCl (pH 7.5), 1 mM MgCl2, 0.5 mM
EDTA, 0.5 mM DTT, 50 mM NaCl, 4% glycerol, 0.05 g/l
polydeoxyinosinic  deoxycytidylic  acid,  and  1  µl  of
[γ-32P]ATP-labeled  oligonucleotide  probes.  The  binding
specificity of the DNA/protein binding was determined by
competitive reactions in which a 100 fold molar excess of
unlabeled NF-κB oligonucleotide was added to the binding
reaction 10 min before the addition of the biotin probe. Mixed
samples were incubated at room temperature (25 °C) for 30
min  and  fractionated  by  electrophoresis  on  a  4%  non-
denaturing polyacrylamide gel in a TBE (Tris-borate EDTA)
buffer that was pre-electrophoresed for 1 h at 100 V. After
electrophoresis,  gels  were  dried  and  autoradiographed  to
detect NF-κB binding activity.
Enzyme-linked  immunosorbent  assay  analysis  of  TNF-α:
TNF-α  protein  was  assayed  using  a  commercial  enzyme-
linked  immunosorbent  assay  (ELISA)  kit  (Biosource
International  Inc.,  Camarillo,  CA)  following  the
manufacturer’s instruction with the sensitivity being 5 pg/ml.
Histopathological  evaluation  and  immunocytochemistry:
Enucleated eyes 14 days after irradiation were placed in 10%
buffered neutral formalin and embedded in paraffin. The 5
μm sagittal sections were then cut, and some of the sections
were  stained  with  Hematoxylin  and  eosin  (H&E)  for  a
histological  examination  under  a  microscope.  For
immunocytochemical analysis, sections cut from the same
paraffin blocks were deparaffinized and rehydrated. Slides
were boiled in a target retrieval solution buffer (Dako, Kyoto,
Japan) in a microwave for 4 min and then placed at room
temperature  (25  °C)  for  20  min.  Endogenous  peroxidase
activity was blocked by addition of 0.3% hydrogen peroxidase
in methanol, and the sections were treated with normal goat
serum and incubated overnight with a monoclonal antibody
against the p65 subunit of activated NF-κB (1:100; Santa Cruz
Biotechnology,  Santa  Cruz,  CA)  at  4  °C.  Thereafter,  a
biotinylated secondary antibody against mouse IgG and an
avidin-biotinylated  peroxidase  complex  (Santa  Cruz
Biotechnology) were used with 3,3′-diaminobenzidine as a
peroxidase  substrate.  Sections  were  counterstained  with
hematoxylin. Negative controls were performed by omitting
the primary antibody.
Statistical  analysis:  χ2  analysis  was  used  to  compare  the
reactivation rates. The Wilcoxon-Mann–Whitney rank sum
test was used for comparison of corneal opacity scores at every
time point. The data from EMSA and ELISA were expressed
as mean±standard error (SE). Differences between groups
were determined by Student’s t-test. A p<0.05 was considered
statistically significant.
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Effects of LOR on the incidence of recurrent virus shedding
and reactivation rate: As shown in Table 1, the daily LOR
treatment was associated with the reduction in the positive
virus  shedding  following  UVB-stimulated  ocular  HSV
recurrence. The positive virus shedding in LOR-treated mice
was  significantly  lower  than  that  in  saline  control  mice,
especially on days 3, 4, and 6. There was no positive viral
shedding in either the mock infected control or LOR control
mice. A significant reduction in the overall reactivation rate
was observed in the mock immunized mice (33/76, 43.4%)
compared with the saline control group (53/76, 69.7%; Table
1; p=0.001).
Effects of LOR on the tissue lesions: As shown in Table 1, on
day  7  after  UVB  irradiation,  the  development  of  stromal
disease was detected in 67.1% (47/70) of the mice in the
saline-treated  group  but  only  38.6%  (27/70)  in  the  LOR-
treated  group.  This  difference  was  statistically  significant
(p=0.001). Similar results were obtained on day 4 after UVB
irradiation (Table 1). Moreover, significant corneal opacity
was observed in reactivated eyes of mice treated with saline.
In contrast, mice receiving LOR demonstrated a significant
reduction in clinical scores compared to the saline-treated
group (Figure 1). Although 82.86% of the saline-treated eyes
developed clinically evident lesions (score 3 or greater) at day
14 after recurrence, only 13.33% of eyes treated with LOR
developed  such  lesions.  Mock-infected  mice  after  UVB
irradiation  developed  mild  and  transient  opacity,  which
disappeared  within  four  days  (data  not  shown).  Taken
together,  these  results  indicate  that  LOR  reduced  the
development of keratitis via inhibition of inflammation.
Effect of LOR on NF-κB activation in the cornea: To evaluate
whether LOR diminished the activity of NF-κB, we performed
EMSA  to  determine  the  levels  of  nuclear  NF-κB  DNA–
binding activity in the cornea after recurrence. As shown in
the EMSA blot, there was a constitutive low expression in the
mock-infected  group  but  prominent  high  intensity  in  the
saline-treated, infected group (Figure 2). HSV-1 recurrence
resulted  in  a  significant  upregulation  of  NF-κB  activity,
shown as a maximal fivefold induction of NF-κB compared
with the mock-infected group. Moreover, an obvious decrease
in  NF-κB  activity  was  found  in  the  LOR-treated  group
compared to the saline-treated group. Since no differences
were observed in NF-κB activity between the mock infected
saline-treated group and the LOR alone group, it seemed that
LOR alone did not have any significant effect on the activity
of NF-κB.
Effect of LOR on TNF-α expression in the cornea: As shown
in  Figure  3,  the  kinetics  and  pattern  of  elevated  TNF-α
Figure 1. Lornoxicam treatment decreases the severity of recurrent
herpetic stromal keratitis. Latently infected mice were consecutively
treated with 0.4 mg/kg of lornoxicam (LOR) or an equal volume of
saline  on  one  day  before  UVB  exposure  and  repeated  on  the
following six days post-UVB exposure. The mean score of corneal
opacity in LOR-treated mice (HSK+LOR) was significantly lower
than that in the saline control mice (HSK), reaching significance on
days 7 to day 21 (p=0.09). The asterisk indicates that p<0.001 when
compared to the HSK group at the corresponding time points.
TABLE 1. NUMBERS OF MICE IN THE DIFFERENT TREATMENT GROUPS WITH VIRAL SHEDDING AND STROMAL DISEASE.
Treatment
group
Positive virus sheddinga(%) Stromal diseaseb (%) Reactivation
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Eyes of mice with latent ocular HSV infection were UVB irradiated (day 0) and swabbed to detect recurrent viral shedding from
days 0 to 7. The eyes were observed under a slit-lamp biomicroscope in a masked fashion. In the table, "a" indicates the number
of eyes shedding virus versus total number of eyes irradiated with UVB and "b" indicates the incidence of stromal opacity in
each group. "c" indicates recurrent disease was defined as stromal opacification for more than two consecutive days and virus
shedding in tears on any day from day 1 to day 7 post-UVB exposure with day 0 swabs serving as the control. D=days post
UVB irradiation. An asterisk indicates that there was a significant difference when compared with the saline-treated group at
the corresponding time points ( range p<0.001–0.080).
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activity. The TNF-α expression in all infected groups were
significantly higher than that in the mock-infected control,
showing a maximal 11.6 fold increase in comparison with the
mock-infected control at day 7. In contrast, the production of
TNF-α was markedly suppressed by LOR treatment before
recurrence. Cornea from the mock-infected mice and from the
LOR  alone  mice  showed  minimal  basal  levels  of  TNF-α
expression (p=0.128).
Effect of LOR on keratitis by histology: As shown in Figure
4, the corneas experiencing recurrent HSK showed significant
extracellular  edema,  pronounced  infiltrate,  and  congestive
blood vessels 14 days after irradiation whereas LOR treatment
ameliorated  the  recurrent  HSK  lesions.  A  significantly
Figure 2. Electrophoretic mobility shift assessment of the DNA-
binding activity of NF-κB in the cornea of different groups. A:
Nuclear extracts were probed for NF-κB binding activity. Lane 1:
mock-infected group (Control); lanes 2, 4, 6, 8, and10: Reactivated,
saline-treated group (HSK) on days 4, 7, 10, 14, and 21, respectively;
lanes 3, 5, 7, 9, and 11: Reactivated, LOR-treated group (HSK+LOR)
on days 4, 7, 10, 14, and 21, respectively; lane 12: mock-infected
group treated with lornoxicam (LOR). The data are representative of
three independent experiments. B: Quantitative analysis is displayed
of NF-κB activity by EMSA at days 4, 7, 10, 14, and 21 after
irradiation in corneas of ICR mice treated with either saline or LOR.
The  bands  were  quantified  using  image  analysis  software
(Bandleader  3.0  software,  Magnitec  Ltd.  Tel  Aviv,  Israel).  The
relative intensity was determined by comparison with that of the
background. The data are presented as mean±standard error of results
from  three  independent  experiments.  EMSA  shows  a  markedly
upregulated activity of NF-κB in the HSK group and HSK+LOR
group compared to levels in the control group, and this upregulation
was dramatically suppressed by LOR treatment at each indicated
time point. The asterisk indicates that p<0.05 when compared to the
control group. The hash mark indicates that p<0.05 for the HSK
+LOR group when compared to the HSK group at the corresponding
time points.
decreased  number  of  inflammatory  cells  and  less
neovascularization were observed in the LOR-treated group
(Figure 4A,B).
Effect of LOR on activated NF-κB immunoreactivity in the
cornea: Immunohistochemical staining was performed with
an antibody against the activated p65 subunit of NF-κB to
evaluate the distribution of NF-κB in the cornea. A similar
expression  pattern  of  NF-κB  in  corneas  from  the  control
(Figure 4C) and LOR alone groups (Figure 4D) was observed,
showing only a faint stain for p65 in the nuclei of the basal
corneal  epithelial  cells.  No  keratocytes  with
immunoreactivity  for  activated  p65  were  detected  in  the
stroma. In contrast, intense and diffuse positive staining for
p65 was demonstrated in the basal corneal epithelial cells and
throughout the stroma in the reactivated, saline-treated group
(Figure 4E). Meanwhile, immunoreactivity of p65 was scant
and reduced in the epithelium and stroma in the LOR-treated
cornea as compared with the saline-treated cornea (Figure 4F).
LOR effectively blocked the nuclear translocation of NF-κB.
Immunoreactivity  was  not  detectable  when  the  primary
antibody was omitted (data not shown), indicating that the
reaction was specific.
DISCUSSION
The pathogenesis of recurrent HSK has become an area of
intense  research.  It  has  been  widely  realized  that  the
progressive visual impairment induced by reactivated HSV-1
infection is largely due to the immune-mediated inflammatory
process rather than the cytopathic effects. Therefore, it has
Figure  3.  TNF-α  expression  in  corneas  of  different  groups
determined by ELISA. The data are presented as the mean±standard
error of results from three independent experiments. ELISA showed
a markedly upregulated activity of NF-κB in infected corneas of
saline-treated mice (HSK) and LOR-treated mice (HSK+LOR) when
compared to levels in the mock-infected cornea (Control). LOR
treatment significantly inhibited TNF-α expression in the cornea at
each indicated time point. The asterisk indicates that p<0.05 when
compared to the control group, and the hash mark denotes that p<0.05
for the HSK+LOR group when compared to the HSK group at the
same time point.
Molecular Vision 2009; 15:1252-1259 <http://www.molvis.org/molvis/v15/a133> © 2009 Molecular Vision
1256been of interest to treat recurrent HSK with anti-inflammatory
drugs.
Our results have shown that LOR, a COX inhibitor, could
not only provide protection against HSK recurrences but also
exert a beneficial effect on the prognosis of recurrent HSK in
a mouse model. Moreover, to the best of our knowledge, this
was the first study demonstrating that LOR exerted its effects
Figure  4.  Influence  of  LOR  on  the  histopathological  and
immunohistochemical studies in mouse corneas 14 days after UV
irradiation. The typical histologic findings of cornea stained with
hematoxylin and eosin (A, B) are shown. A: The cornea in the saline-
treated group shows marked inflammation, obvious edema, profound
neovascularization, and significant hypercellularity in the stroma.
B: The cornea in the LOR-treated group exhibits only scattered
inflammatory  cells,  mild  stromal  swelling,  and  less
neovascularization.  Corneal  tissues  (C-F)  were  analyzed  by
immunohistochemistry  to  determine  the  expression  of  NF-κB.
Immunohistochemical staining with an antibody against activated
NF-κB was performed to detect the expression of NF-κB. Sections
incubated without a primary antibody served as negative controls.
All tissue sections were counterstained with hematoxylin. These
samples were representative of all corneas examined. Brown staining
indicates activated NF-κB. C,D: The cornea in the mock-infected
group and the cornea in LOR alone group show that NF-κB activity
is  only  observed  very  faintly  in  the  base  cells  of  epithelium
(arrowheads). E: Recurrence induced wide spread positive staining
of NF-κB, which was most robust in the stroma (arrows) of the saline-
treated group. F: Scant immunoreactivity of NF-κB was observed in
the  stroma  of  the  LOR-treated  group  (arrows).  Original
magnifications, 400X.
through the inhibition of NF-κB and subsequent decrease in
expression of cytokines, reducing inflammatory response.
At the cellular level, LOR likely prevents recurrence and
inhibits stromal opacity directly by reducing the expression of
cytokines. Consistent with previous reports [7], we observed
a significant upregulation of TNF-α level in mice with UVB-
induced HSV reactivation [16,17]. TNF-α, whose expression
is regulated by NF-kB activation, is among the first to be
produced in chronic inflammation and tissue damage during
the development of HSK [7,8,18]. It enhances synthesis of
inflammatory mediators and contributes to the recruitment of
inflammatory  cells.  In  this  study,  LOR  inhibited  the
expression of TNF-α as well as the development of corneal
inflammation.
Given the pivotal role NF-κB plays in the immune system
and  inflammatory  diseases,  we  investigated  its  activation
during recurrent HSK in mice. Consistent with several reports
addressing  the  role  of  NF-κB  activation  in  corneal
neovascularization and lipopolysaccharide-induced keratitis
[19,20], we clearly demonstrate that there is a significant and
persistent  upregulation  of  activated  NF-κB  in  the  cornea
during HSK recurrence. The NF-κB p65 immunoreactivity
was  associated  with  corneal  inflammation  leading  to
neovascularization  and  opacity.  The  ameliorated  clinical
lesion of HSK after LOR treatment was accompanied by a
dramatic reduction in recurrence-induced activation of NF-
κB. At the molecular level, the increased expression of TNF-
α is due to the activation of the transcriptional factor, NF-κB
[7,8]. On the other hand, TNF-α can act as a potent inducer of
NF-κB activation [21]. Then sustained NF-κB activation and
elevated  expression  of  TNF-α  trigger  the  perpetuated
inflammatory  reactions.  In  the  present  study,  we  have
demonstrated that LOR treatment blocked signaling through
NF-κB, dampened the pro-inflammatory response to HSV-1,
and thereby reduced corneal opacity. Previous reports have
shown that NF-κB can function as an upstream regulator of
COX-2, controlling its transcription [22,23]. COX inhibitors
can exert their anti-inflammatory activities by blocking the
NF-κB signaling pathways via one or several steps in the
activation cascade [24-27]. Moreover, the non-steroidal anti-
inflammatory drugs (NSAIDs) may exert their effects via the
NF-κB pathway, independent of COX inhibition [28]. The
concrete  mechanism  by  which  LOR  inhibits  the  NF-κB
activation has yet to be elucidated.
Previous  reports  have  unveiled  that  HSV-1  interferes
with  cellular  signal  transduction  and  transcription  factor
activity, especially the activation of NF-κB, thus promoting
viral replication and expression of pro-inflammatory proteins.
Accordingly, HSV-1 infection can act as a stimulant for NF-
κB expression. Moreover, this persistent activation of NF-κB
is one of the immune evasion tactics that HSV-1 has acquired
to limit the efficacy of innate or acquired immunity [9-12]. As
such,  the  suppressed  viral  replication  may  be  mediated
Molecular Vision 2009; 15:1252-1259 <http://www.molvis.org/molvis/v15/a133> © 2009 Molecular Vision
1257through the inhibition of NF-κB activity. In support of this
concept, glucocorticoid, resveratrol, and tetranortriterpenoid
treatment have been shown to effectively inhibit the activation
of NF-κB and thereby effectively suppress HSV-1 infection
[29-32]. UVB irradiation functions as an inducer for viral
reactivation in the recurrent HSK model. We speculate that
UV irradiation induces the elevated NF-κB activation and
subsequent  mediator  production,  leading  to  herpes  viral
reactivation. Although we have shown in a previous study the
therapeutic effect of lornoxicam on corneal damage after high
intensity UVB irradiation via inhibition of NF-kB activation,
the concrete mediators and detailed mechanisms between NF-
κB activation and viral reactivation need further investigation
[33]. Since patients undergoing excimer laser keratectomy or
penetrating keratoplasty are at high risk for developing herpes
viral infection or reactivation [34-37], further studies will
address the potential efficacy of prophylactic LOR treatment
in those patients.
Of note, since NF-κB is essential in maintaining normal
host defense and broadly involved in multiple cell regulation
[29,38], precautions should be taken when considering the
targeting  NF-kB  as  a  novel  therapeutic  approach.  In  the
current study, valuable information is provided by the LOR
alone groups in which the NF-κB signaling pathway was
selectively unaffected under a similar physiologic response
after  LOR  treatment.  Although  we  did  not  observe  any
abnormalities in mice that were systemically administered
LOR  until  the  end  of  the  experiment,  it  is  uncertain  if
undesirable effects may occur after long-term usage.
In  conclusion,  based  on  previous  reports  showing
antiviral activity of COX inhibitors against ocular infection
with HSV-1 [4-6], we extended those previous findings by
exploring the intrinsic mechanism underlying the protective
activity of LOR. The results reported herein may shed new
light  on  the  development  of  novel  therapeutic  and
prophylactic approaches to treating recurrent HSK.
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